Literature DB >> 6826203

Effect of angiotensin II on macrophage functions.

G Fóris, B Dezsö, G A Medgyesi, G Füst.   

Abstract

Angiotensin II (At II) has been shown to inhibit in vitro the IgG2a-mediated rosette formation of 51Cr-sheep red blood cells (SRBC) by provoked peritoneal macrophages (PM) at 10(-5)-10(-6) M concentrations. The decreased rosette formation was associated with an increased phagocytosis. It was found that the enhanced rosette formation at 10(-7) M hormone concentration was followed by diminished phagocytosis via Fc gamma receptors (R). Processes mediated through Fc microR were affected only after incubation with 10(-5) M of At II. The attachment and subsequent phagocytosis through C3bR was markedly enhanced by At II in a dose-dependent way. Thus, the relative phagocytosis (RP) through both FcRs was significantly enhanced by 10(-5), i.e. by 10(-5)-10(-6) M of At II, but lowered at 10(-7) M hormone concentration. In addition, there was no RP enhancing effect of At II after preincubation with 10(-5) M of indomethacin (IM), indicating the significance of prostaglandins (PG) in the hormone effect. The medium containing 5 mM of EGTA diminished both the RP enhancing and inhibiting effects of At II. The RP mediated by C3b was not affected by At II, IM or EGTA. The intracellular killing capability, measured by chromium release from Candida albicans, was not altered or even slightly diminished after At II treatment of PMs.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6826203      PMCID: PMC1454028     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  17 in total

1.  Angiotensin II stimulation of prostaglandin production in cultured human vascular endothelium.

Authors:  M A Gimbrone; R W Alexander
Journal:  Science       Date:  1975-07-18       Impact factor: 47.728

2.  Binding sites for angiotensin II in human mononuclear leucocytes.

Authors:  K Shimada; Y Yazaki
Journal:  J Biochem       Date:  1978-10       Impact factor: 3.387

3.  Enhancement of the inotropic action of glucagon by small concentration of angiotensin.

Authors:  K Inoue; H Smulyan; E Mucha; R H Eich
Journal:  Jpn Heart J       Date:  1973-05

4.  Role of binding through C3b and IgG in polymorphonuclear neutrophil function: studies with trypsin-generated C3b.

Authors:  S L Newman; R B Johnston
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

5.  Effect of prostaglandins on phagocytosis of sheep erythrocytes by mouse peritoneal macrophages.

Authors:  E Razin; S Bauminger; A Globerson
Journal:  J Reticuloendothel Soc       Date:  1978-04

6.  Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide.

Authors:  S M Wahl; L M Wahl; J B McCarthy; L Chedid; S E Mergenhagen
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

7.  Third component of human complement: purification from plasma and physicochemical characterization.

Authors:  B D Tack; J W Prahl
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

8.  A chromium release assay for phagocytic killing of Candida albicans.

Authors:  M Yamamura; J Boler; H Valdimarsson
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

9.  Effects of angiotensin, catecholamines and cyclic AMP on calcium storage in aortic microsomes.

Authors:  M Baudouin-Legros; P Meyer
Journal:  Br J Pharmacol       Date:  1973-02       Impact factor: 8.739

10.  The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent.

Authors:  A E Bolton; W M Hunter
Journal:  Biochem J       Date:  1973-07       Impact factor: 3.857

View more
  10 in total

1.  Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway.

Authors:  C Nataraj; M I Oliverio; R B Mannon; P J Mannon; L P Audoly; C S Amuchastegui; P Ruiz; O Smithies; T M Coffman
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

2.  Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis.

Authors:  Masashi Nishida; Hidehiko Fujinaka; Taiji Matsusaka; James Price; Valentina Kon; Agnes B Fogo; Jeffrey M Davidson; MacRae F Linton; Sergio Fazio; Toshio Homma; Hiroaki Yoshida; Iekuni Ichikawa
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

3.  Bidirectional effect of met-enkephalin on macrophage effector functions.

Authors:  G Fóris; G A Medgyesi; M Hauck
Journal:  Mol Cell Biochem       Date:  1986-02       Impact factor: 3.396

Review 4.  Drug Therapy for Heart Valve Diseases.

Authors:  Jeffrey S Borer; Abhishek Sharma
Journal:  Circulation       Date:  2015-09-15       Impact factor: 29.690

5.  Impairment of granulomatous inflammatory response to Histoplasma capsulatum by inhibitors of angiotensin-converting enzyme.

Authors:  G S Deepe; C L Taylor; L Srivastava; W E Bullock
Journal:  Infect Immun       Date:  1985-05       Impact factor: 3.441

Review 6.  Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases.

Authors:  Aina He; Guo-Ping Shi
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

7.  Are angiotensin converting enzyme inhibitors beneficial in patients with aortic stenosis?

Authors:  D M Shavelle
Journal:  Heart       Date:  2005-10       Impact factor: 5.994

8.  Angiotensin II increases host resistance to peritonitis.

Authors:  K Rodgers; S Xiong; T Espinoza; N Roda; S Maldonado; G S diZerega
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

9.  The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention.

Authors:  M Texter; R S Lees; B Pitt; R E Dinsmore; A C Uprichard
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

10.  Captopril enhances in vitro human lymphocyte thymidine incorporation.

Authors:  M R Simon; J V Weinstock; R M Morrell; L D Roi; L M Howard
Journal:  Agents Actions       Date:  1984-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.